Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ohio State University Comprehensive Cancer Center
PRIMARY OBJECTIVES:
I. Determine whether ILN biochip can be used to detect molecular marker(s) to monitor treatment response in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
II. Determine whether ILN biochip can promote early detection of disease relapse in patients with DLBCL.
OUTLINE:
Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed treatment naive DLBCL. Subtypes including high grade B-cell lymphoma, not otherwise specified (NOS) and de-novo DLBCL including germinal center B-cell type (GCB) and non-GCB subtypes.
Intent to receive entire care (treatment and follow-up) at Ohio State University (OSU).
Receiving treatment with curative intent.
Receiving planned 6 cycles of chemotherapy.
Ability to consent.
You may not be if
Transformed lymphomas.
DLBCL with leukemic presentation.
Primary central nervous system (CNS) lymphoma.
Participating in other clinical trial/ receiving experimental therapy.
Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation.
Pregnancy (positive serum or urine pregnancy test) or breast feeding.